Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652559 | 0.93 | LPAR1 (0.46) | LPAR1LPAR3ENPP2 | |
| SCHEMBL17772555 | 0.91 | LPAR1 (0.46) | LPAR1LPAR3ENPP2 | |
| SCHEMBL17772529 | 0.90 | DGKA (0.46) | LPAR1LPAR3ENPP2DGKA | |
| SCHEMBL14725883 | 0.90 | LPAR1 (0.45) | LPAR1LPAR3ENPP2 | |
| SCHEMBL19652555 | 0.90 | DGKA (0.46) | LPAR1LPAR3ENPP2DGKA | |
| SCHEMBL17772536 | 0.90 | PRKCA (0.47) | LPAR1LPAR3ENPP2DGKA | |
| SCHEMBL17772527 | 0.90 | PRKCA (0.47) | LPAR1LPAR3ENPP2DGKA | |
| SCHEMBL19652560 | 0.90 | PRKCA (0.45) | LPAR1LPAR3ENPP2 | |
| SCHEMBL17772532 | 0.90 | DGKA (0.46) | LPAR1LPAR3ENPP2DGKA | |
| SCHEMBL17772550 | 0.90 | PRKCA (0.47) | LPAR1LPAR3ENPP2DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311403-A1 | Method of Using Organic Compounds | MGLL, GK, LIPC | LPAR1 2019/4885LPAR3 1772/4885ENPP2 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.